Abstract
Retinoids' effects on cell growth and differentiation are mediated by nuclear retinoid receptors, which are ligand-activated transcription enhancing factors. Because the expression of the retinoic acid receptor β (RARβ) gene, which is located on chromosome 3p24, is diminished in premalignant and malignant tissues it has been proposed that it acts as a tumor suppressor. To test the hypothesis that RARβ loss leads to retinoid resistance, we studied several karyotyped head and neck squamous carcinoma (HNSCC) cell lines (UMSCC-17A, -17B, -22A, -22B, and -38) with deletion of one chromosome 3p arm. RARβ mRNA was neither detected nor induced by retinoic acid in these cells, whereas it was expressed and induced by retinoic acid in two other HNSCC cell lines (1483 and 183) without 3p deletion. Methylation of the RARβ gene promoter was detected in the 17B and 22B cells that failed to express RARβ but no methylation was found in 183A cells that did express RARβ mRNA. Responsiveness of HNSCC cells to several retinoids in assays of growth inhibition and colony formation, was rank ordered as: 22B>1483>38>183>17B. Additionally, retinoid response elements were transactivated in 22B more efficiently than in 17B cells. These results indicate that loss of RARβ expression does not necessarily lead to loss of growth inhibition by retinoids or to a block of retinoid signaling.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Abbreviations
- ATRA:
-
All-trans-retinoic acid
- 9-cisRA:
-
9-cis retinoic acid
- RAR:
-
retinoic acid receptor
- RXR:
-
retinoid X receptor
- RARE:
-
retinoic acid response element
- RXRE:
-
retinoid X response element
- CVC:
-
crystal violet
- RT-PCR:
-
reverse transcription polymerase chain reaction
- CAT:
-
chloramphenicol acetyl transferase
- LOH:
-
loss of heterozygosity.
References
Ausubel FM, Brent R, Kingston RE, Moore DD, Seiderman JG, Smith JA, Struhl K (eds) . 1998 Current Protocols in Molecular Biology John Wiley & Sons, New York, NY
Berard J, Laboune F, Mukuna M, Masse S, Kothary R, Bradley WE . 1996 FASEB J. 10: 1091–1097
Bovenzi V, Le NL, Cote S, Sinnett D, Momparler LF, Momparler RL . 1999 Anticancer Drugs 10: 471–476
Buchhagen DL, Worsham MJ, Dyke DL, Carey TE . 1996 Head Neck 18: 529–537
Burge-Bottenbley A, Shklar G . 1983 Nutr. Cancer 5: 121–129
Carey TE, Van Dyke DL, Worsham MJ, Bradford CR, Babu VR, Schwartz DR, Hsu S, Baker SR . 1989 Cancer Res. 49: 6098–6107
Chambon P . 1996 FASEB J. 10: 940–954
Chirgwin JM, Pryzbyla AE, MacDonald GR, Walsh GL, Rutter WJ . 1979 Biochemistry 18: 5294–5299
Cote S, Sinnett D, Momparler RL . 1998 Anticancer Drugs 9: 743–750
Crowe DL, Hu L, Gudas LJ, Rheinwald JG . 1991 Differentiation 48: 199–208
de The H, Vivanco-Ruiz MM, Tiollais P, Dejean A . 1990 Nature 343: 177–180
Ferrari N, Pfeffer U, Tosetti F, Brigati C, Vidali G . 1994 Exp. Cell. Res. 211: 121–126
Gebert JF, Moghal N, Frangioni JV, Sugarbaker DJ, Neel BG . 1991 Oncogene 6: 1859–1868
Grenman R, Carey TE, McClatchey KD, Wagner JG, Pekkola-Heino K, Schwartz DR, Wolf GT, Lacivita LP, Ho L, Baker SR, Krause CJ, Lichter AS . 1991 Cancer 67: 2741–2747
Hayashi K, Yokozaki H, Naka K, Yasui W, Yajin K, Lotan R, Tahara E . 2000 Cancer Lett. 15: 199–208
Hayashi K, Yokozaki H, Naka K, Yasui W, Lotan R, Tahara E . 2001 Jpn. J. Cancer Res. 92: 42–50
Herman JG, Graff JR, Myohanen S, Nelkin BD, Baylin SB . 1996 Proc. Natl. Acad. Sci. USA 93: 9821–9826
Hoffmann B, Lehmann J, Zhang X-K, Hermann T, Graupner G, Pfahl M . 1990 Mol. Endocrinol. 4: 1734–1743
Hong WK, Endicott J, Itri LM, Doos W, Batsakis JG, Bell R, Fofonff S, Byers R, Atkinson EN, Vaughan C, Toth BB, Kramer A, Dimerry IW, Skipper P, Strong S . 1986 N. Engl. J. Med. 315: 1501–1505
Hong WK, Lippman SM, Itri LM, Karp DD, Lee JS, Byers RM, Schantz SP, Kramer AM, Lotan R, Peters L, Dimery IW, Brown BW, Goepfert H . 1990 N. Engl. J. Med. 323: 795–801
Houle B, Rochette-Egly C, Bradley WE . 1993 Proc. Natl. Acad. Sci. USA 90: 985–989
Hu L, Crow DL, Rheinwald JG, Chambon P, Gudas LJ . 1991 Cancer. Res. 51: 3972–3981
Klein-Hitpass L, Ryffel GU, Heitlinger E, Cato ACB . 1988 Nucleic. Acids. Res. 16: 647–648
Krause CJ, Carey TE, Ott RW, Hurbis C, McClatchey KD, Regezi JA . 1981 Arch. Otolaryngol. 107: 703–710
Kueng W, Silber E, Eppenberger U . 1989 Anal. Biochem. 182: 16–19
Latif F, Fivash M, Glenn G, Tory K, Orcutt ML, Hampsch K, Delisio J, Lerman M, Cowan J, Beckett M, Weichselbaum R . 1992 Cancer Res. 52: 1451–1456
Le Q, Dawson MI, Soprano DR, Soprano KJ . 2000 Oncogene 19: 1457–1465
Lotan R, Lotan D, Sacks P . 1991 Methods in Enzymology: Retinoids. Packer L (ed) Academic Press: Orlando pp. 100–110
Lotan R, Xu XC, Lippman SM, Ro JY, Lee JS, Lee JJ, Hong WK . 1995 N. Engl. J. Med. 332: 1405–1410
Lotan R . 1994 Cancer Res. 54: 1987s–1990s
Maestro R, Gasparotto D, Vukosavljevic T, Barzan L, Sulfaro S, Boiocchi M . 1993 Cancer Res. 53: 5775–5779
Mangelsdorf DJ, Evans RM . 1995 Cell 83: 841–850
Mangelsdorf DJ, Umesono K, Kliewer SA, Borgmeyer U, Ong ES, Evans RM . 1991 Cell 66: 555–561
Mattei MG, de The H, Mattei JF, Marchio A, Tiollais P, Chambon P . 1988 Hum. Genet. 80: 189–190
McGregor F, Wagner E, Felix D, Soutar D, Parkinson K, Harrison PR . 1997 Cancer Res. 57: 3886–3889
Neel BG, Hayward WS, Robinson HL, Fang J, Astrin SM . 1981 Cell 23: 323–334
Oridate N, Esumi N, Lotan D, Hong WK, Rochette-Egly C, Chambon P, Lotan R . 1996 Oncogene 12: 2019–2028
Oridate N, Lotan D, Lotan R . 1996 In Vitro Cell Dev. Biol. 32: 192–193
Picard E, Seguin C, Monhoven N, Rochette-Egly C, Siat J, Borrelly J, Martinet Y, Martinet N, Vignaud JM . 1999 J. Natl. Cancer Inst. 91: 1059–1066
Sacks PG, Parnes SM, Gallick GE, Mansouri Z, Lichtner R, Satya-Prakash KL, Pathak S, Parsons DF . 1988 Cancer Res. 48: 2858–2866
Schwartz JL, Frim SR, Shklar G . 1985 Nutr. Cancer 7: 77–84
Shalinsky D, Bischoff R, Gregory ML, Gottardis MM, Hayes JS, Lamph WW, Heyman RA, Shirely MA, Cooke TA, Davies PJA, Thomazy V . 1995 Cancer. Res. 55: 3183–3191
Shalinsky DR, Bischoff ED, Lamph WW, Zhang L, Boehm MF, Davies PJ, Nadzan AM, Heyman RA . 1997 Cancer. Res. 57: 162–168
Sirchia SM, Ferguson AT, Sironi E, Subramanyan S, Orlandi R, Sukumar S, Sacchi N . 2000 Oncogene 19: 1556–1563
Sun SY, Yue P, Mao L, Dawson MI, Shroot B, Lamph WW, Heyman RA, Chandraratna RA, Shudo K, Hong WK, Lotan R . 2000 Clin. Cancer Res. 6: 1563–1573
Umesono K, Murakami KK, Thompson CC, Evans RM . 1991 Cell 65: 1255–1262
Van Dyke DL, Worsham MJ, Benninger MS, Krause CJ, Baker SR, Wolf GT, Drumheller T, Tilley BC, Carey TE . 1994 Genes, Chromosomes Cancer 9: 192–206
Virmani AK, Rathi A, Zochbauer-Muller S, Sacchi N, Fukuyama Y, Bryant D, Maitra A, Heda S, Fong KM, Thunnissen F, Minna JD, Gazdar AF . 2000 J. Natl. Cancer Inst. 2: 1303–1307
Wan H, Dawson MI, Hong WK, Lotan R . 1998 J. Biol. Chem. 273: 26915–26922
Wan H, Oridate N, Lotan D, Hong WK, Lotan R . 1999 Cancer Res. 59: 3518–3526
Widschwendter M, Berger J, Hermann M, Muller HM, Amberger A, Zeschnigk M, Widschwendter A, Abendstein B, Zeimet AG, Daxenbichler G, Marth C . 2000 J. Natl. Cancer Inst. 92: 826–832
Xu X-C, Ro JY, Lee JS, Shin DM, Hong WK, Lotan R . 1994 Cancer Res. 54: 3580–3587
Youssef EM, Issa J-P, Mao L, Hong WK, Lotan R . 2001 Proc. Amer. Assoc. Cancer Res. 42: 550 abstract 2957
Zou CP, Clifford JL, Xu XC, Sacks PG, Chambon P, Hong WK, Lotan R . 1994 Cancer Res. 54: 5479–5487
Zou CP, Hong WK, Lotan R . 1999 Differentiation 64: 123–132
Acknowledgements
This study was supported by United States Public Health Service Grant PO1 CA52051 from the National Cancer Institute and P50 DE11906 from the National Institute of Dental and Craniofacial Research. CP Zou was supported by Training Grant R25 CA57730 from the National Cancer Institute (Robert Chamberlain, P.I.). R. Lotan is the incumbent of the Irving and Nadine Mansfield and Robert David Levitt Cancer Research Chair. We thank Dr P Sacks (Memorial Sloan-Kettering Cancer Center, New York, NY, USA) for two HNSCC cell lines and Drs Bollag and Shroot for retinoids.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Zou, CP., Youssef, E., Zou, CC. et al. Differential effects of chromosome 3p deletion on the expression of the putative tumor suppressor RARβ and on retinoid resistance in human squamous carcinoma cells. Oncogene 20, 6820–6827 (2001). https://doi.org/10.1038/sj.onc.1204846
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1204846
Keywords
This article is cited by
-
Genetic imbalances detected by multiplex ligation-dependent probe amplification in a cohort of patients with oral squamous cell carcinoma—the first step towards clinical personalized medicine
Tumor Biology (2014)
-
Molecular Characterization of Head and Neck Cancer
Molecular Diagnosis & Therapy (2012)
-
DNA hypermethylation markers of poor outcome in laryngeal cancer
Clinical Epigenetics (2010)
-
Hyperacetylation enhances the growth-inhibitory effect of all-trans retinoic acid by the restoration of retinoic acid receptor β expression in head and neck squamous carcinoma (HNSCC) cells
Cancer Chemotherapy and Pharmacology (2005)